💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sildenafil Citrate

CHEMBL1737 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
666.7 g/mol
LogP
—
Phase
4

A citrate salt form of sildenafil with the same therapeutic properties. Originally developed for heart conditions, this medication relaxes and widens blood vessels by blocking an enzyme called PDE5, increasing blood flow.

分子量

666.7000 g/mol

TPSA

250.00 Ų

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Benign Prostatic Hyperplasia Glaucoma Cardiovascular Disease Age-Related Macular Degeneration Respiratory Disease Non-Small Cell Lung Cancer Osteoporosis Chronic Obstructive Pulmonary Disease Parkinson's Disease Migraine Schizophrenia Systemic Lupus Erythematosus Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer HIV/AIDS Hepatitis C Heart Failure Prostate Cancer Colorectal Cancer

作用機序

Selective PDE5 inhibitor increasing cGMP.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Selective PDE5 inhibitor increasing cGMP.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28;7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

                

                

                

                    
                    

                        
Molecular Formula

                        
C28H38N6O11S

                    

                    
                    

                        
HBD / HBA

                        
5 / 15

                    

                    
                    

                        
回転可能結合数

                        
12

                    

                    
                    
                    

                        
重原子数

                        
46

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
A citrate salt form of sildenafil with the same therapeutic properties. Originally developed for heart conditions, this medication relaxes and widens blood vessels by blocking an enzyme called PDE5, increasing blood flow.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective PDE5 inhibitor increasing cGMP.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Sildenafil Citrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1737.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 135413523.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.